NHS Medtech Demand-Side Should Be Greater Priority, Says UK Industry In AAR Response
Executive Summary
The Accelerated Access Review, part of the UK's renewed push to speed access to innovations for system efficiency, cost savings and outcomes improvements, strikes most of the right notes, but there is still room for improvement in the framework of innovation adoption by the NHS, according to an industry-commissioned response to the review.
You may also be interested in...
UK Outlook 2018: Companies Need To Quantify Brexit Risk And Find A New Place In The World
With the clock running down on Brexit, bemused UK medtechs are ready to seize any information that helps them chart a way forward on trading with the EU in the absence of solid directions from the government. Frustrated by the Brexit vacuum, local manufacturers are actively looking to build businesses beyond the EU and focusing on innovation adoption at home, as ABHI policy director Richard Phillips explains.
UK Outlook 2018: Medtech Readies For Change To FOM System Of Value-Based Procurement
For UK medtech companies, a new NHS value-based procurement system is coming in the shape of the Future Operating Model. ABHI COO Nishan Sunthares explains what the FOM will mean for UK medtechs when it applies fully later this year.
UK Medtech To Leverage Accelerated Access Opportunity, Regardless Of The 'B' Word
The UK devices and diagnostics industries were quick to react to the long-overdue government response to the fall 2016 Accelerated Access Review, a proposal to fast-track innovation into the NHS to the benefit of UK science, patients and the economy. Coinciding with Brexit, it is a fine-sounding plan, but will there be practical follow-through for medtech too?